What is Fairtility?
Fairtility is at the forefront of revolutionizing the IVF landscape by leveraging artificial intelligence to foster transparency and improve success rates. Their flagship product, CHLOE (Cultivating Human Life through Optimal Embryos), is a proprietary AI-based decision support tool designed to offer clinicians complete insight into the clinical and laboratory parameters influencing IVF outcomes. Initially launched with CHLOE EQ, an advanced embryo grading platform, Fairtility is strategically expanding CHLOE's capabilities to encompass the entire IVF journey, from initial infertility cause assessment to optimizing embryo transfer. This data-driven approach aims to demystify the complex IVF process and empower better clinical decisions.
How much funding has Fairtility raised?
Fairtility has raised a total of $18.5M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$15M
Angel/Seed (2020): $3.5M, investors not publicly disclosed
Series A (2022): $15M led by Nacre Capital and Gurnet Point Capital
Key Investors in Fairtility
Nacre Capital
Nacre Capital is a venture capital firm specializing in the creation and growth of disruptive startups leveraging deep technologies. They provide comprehensive support, including financial, business development, and legal assistance, to help transform innovative ideas into market-leading companies.
Gurnet Point Capital
Gurnet Point Capital is a healthcare-focused investment fund with significant capital allocation, supporting entrepreneurs in building next-generation companies across life sciences and medical technologies. They employ a hybrid venture and private equity investment strategy.
What's next for Fairtility?
With its recent major strategic investment, Fairtility is poised for significant expansion and further development of its AI-driven IVF solutions. The substantial capital raised, reflected in the $18.5M in total funding, will likely fuel advancements in CHLOE's capabilities, potentially extending its reach across the full spectrum of fertility treatments. This strategic financing suggests a strong market validation for Fairtility's innovative approach to improving IVF success rates through AI and transparency. The company is expected to enhance its technological infrastructure, broaden its clinical partnerships, and potentially scale its operations globally to meet the growing demand for advanced fertility solutions.
See full Fairtility company page
